Smurf2 expression is decreased in triple-negative breast cancer tissues. (A) Immunohistochemistry for Smurf2 was conducted using human mammary tissues including benign mammary epithelia, ductal carcinomas in situ (DCIS), ER+/PR + and triple-negative (TN) invasive carcinomas. Upper left panel shows x10 magnification, and the other panels show x20 pictures with x40 magnified views. (B) Percent of Smurf2-positive cells in ER+/PR + (n = 47) and TN (n = 43) breast cancer specimens. To quantify focal loss of Smurf2 expression in carcinoma regions, immunohistochemical labeling of Smurf2 was scored according to the following five categories: 0 (Smurf2+ cells in carcinoma tissues: 0-5%), 1+ (6%-25%), 2+ (25%-50%), 3+ (50%-75%), and 4+ (>75%). Data are shown as mean + SEM with the p value for statistical significance.